• Record: found
  • Abstract: found
  • Article: not found

[Intralesional treatment of classical Kaposi sarcoma with interferon-alpha].

Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete

Aged, therapy, pathology, immunology, Skin Neoplasms, Sarcoma, Kaposi, Recombinant Proteins, drug effects, Leukocyte Count, administration & dosage, Interferon-alpha, Injections, Intralesional, Immune Tolerance, Humans, Female, CD4-Positive T-Lymphocytes, CD4-CD8 Ratio

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      A 71-year-old female patient with classic Kaposi sarcoma (sarcoma idiopathicum haemorrhagicum multiplex) of the lower legs and one hand was treated with intralesional recombinant interferon alpha 2b. After 6 consecutive weeks of intratumoral injection of 1-3 million IU interferon-alpha 2b (Intron A) in three marked lesions, complete remission of intralesionally treated and of untreated tumours was observed. Even 9 months after treatment, the patient is still in complete remission. We conclude that this low dose and well-tolerated treatment schedule with interferon-alpha 2b is effective and a good alternative to radiation or chemotherapy in Kaposi sarcoma.

      Related collections

      Author and article information



      Comment on this article